Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

BRAINTEASER

Financiado

Cerrado

BRinging Artificial INTelligencE home for a better cAre of amyotrophic lateral s...

BRinging Artificial INTelligencE home for a better cAre of amyotrophic lateral sclerosis and multiple SclERosis Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS) are chronic diseases characterized by progressive or alternate impairment of neurological functions (motor, sensory, visual, cognitive). Patients have to manage alter... ver más

31/12/2024

UPM

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

UNIVERSIDAD POLITÉCNICA DE MADRID No se ha especificado una descripción o un objeto social para esta compañía.

Total investigadores 3947

Fecha límite participación Sin fecha límite de participación.

Ver 13 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-12-31

SC1-DTH-02-2020: Personalised early risk prediction,...

I+D

Cerrada hace 4 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

13 Participantes

UPM

680.00K€ | Lider

CIENCIAS ULISBOA

N.D. | Participante

BELIT DOO BEOGRAD IT AND E-C...

456.88K€ | Participante

iMM

362.57K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

AI-PROGNOSIS Artificial intelligence-based Parkinson’s disease risk asses... 5M€ Cerrado

MES-CoBraD Multidisciplinary Expert System for the Assessment Managem... 6M€ Cerrado

ALAMEDA Bridging the Early Diagnosis and Treatment Gap of Brain Dise... 6M€ Cerrado

TIN2009-13891 DISEÑO Y EVALUACION DE HERRAMIENTAS COMPUTACIONALES INTELIGE... 12K€ Cerrado

STRATIFYHF Artificial intelligence-based decision support system for ri... 4M€ Cerrado

OSCANN Diagnosing platform for neurological and mental disorders ba... 71K€ Cerrado

Duración del proyecto: 48 meses Fecha Inicio: 2020-12-09
Fecha Fin: 2024-12-31

Líder del proyecto

UNIVERSIDAD POLITÉCNICA DE MADRID No se ha especificado una descripción o un objeto social para esta compañía.

Total investigadores 3947

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS) are chronic diseases characterized by progressive or alternate impairment of neurological functions (motor, sensory, visual, cognitive). Patients have to manage alternated periods in hospital with care at home, experiencing a constant uncertainty regarding the timing of the disease acute phases and facing a considerable psychological and economic burden that also involves their caregivers. Clinicians, on the other hand, need tools able to support them in all the phases of the patient treatment, suggest personalized therapeutic decisions, indicate urgently needed interventions. Artificial Intelligence is the key to successfully satisfy these needs to: i) better describe disease mechanisms; ii) stratify patients according to their phenotype assessed all over the disease evolution; iii) predict disease progression in a probabilistic, time dependent fashion; iv) investigate the role of the environment; v) suggest interventions that can delay the progression of the disease. BRAINTEASER will integrate large clinical datasets with novel personal and environmental data collected using low-cost sensors and apps. Software and mobile apps will be designed embracing an agile and user-centred design approach, accounting for the technical, medical, psychological and societal needs of the specific users. BRAINTEASER will implement a system able to guarantee cybersecurity and data ownership to the patients; will provide quantitative evidence of benefits and effectiveness of using AI in health-care pathways implementing a proof-of-concept of its use in real clinical setting. Procedural requirements that support Software as Medical Device certification will be used involving clinicians and patients stakeholders and producing a set of recommendations for public health authorities. Results will be disseminated accordingly to an open science paradigm under the European Open Science Cloud initiative.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores